1. T-Cell Exhaustion: Can We Overcome It in Cancer?

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. T Cell Exhaustion

6. Tumor Microenvironment

7. Overcoming T-Cell Dysfunction

8. Approved Checkpoint Inhibitors as of June 2018

9. Tumor Types Where PD-1/PD-L1 Inhibitors Are Approved as of June 2018

10. Barriers to Overcoming T-Cell Dysfunction

11. Co-Inhibitory and Co-Stimulatory Molecules

12. Caution in Developing New Molecules

13. New Immune Checkpoint Targets

14. Anti-LAG-3 Antibodies in Development

15. Cytokines

16. NKTR-214

17. CD47

18. Costimulatory Molecules

19. Other Approaches

20. HDAC Inhibitors

21. Further Approaches

22. Concluding Remarks

23. Abbreviations

24. Abbreviations (cont)